CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial-Reference-Cited by-同舟云学术

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

Published:2023-03 Issue:3 Volume:10 Page:e191-e202
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Sallman David A,Kerre Tessa,Havelange Violaine,Poiré Xavier,Lewalle Philippe,Wang Eunice S,Brayer Jason B,Davila Marco L,Moors Ine,Machiels Jean-Pascal,Awada Ahmad,Alcantar-Orozco Erik M,Borissova Rossitza,Braun Nathalie,Dheur Marie-Sophie,Gilham David E,Lonez Caroline,Lehmann Frédéric F,Flament Anne

Publisher

Elsevier BV

Subject

Hematology

Reference32 articles.

1. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19;Braendstrup;Cytotherapy,2020

2. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma;Oriol;Ther Adv Hematol,2021

3. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of acute myeloid leukaemia;Perna;Cancer Cell,2017

4. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo;Baroni;J Immunother Cancer,2020

5. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells;Gill;Blood,2014

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates on CAR T cell therapy in multiple myeloma;Biomarker Research;2024-09-12

2. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies;Blood Reviews;2024-09

3. Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome;Pharmaceutical Research;2024-08-26

4. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention;Frontiers in Immunology;2024-08-26

5. Beyond BCMA: newer immune targets in myeloma;Blood Advances;2024-08-16